|1.||Saxne, Tore: 8 articles (01/2015 - 01/2003)|
|2.||Saxne, T: 8 articles (01/2010 - 08/2000)|
|3.||Heinegård, Dick: 7 articles (07/2014 - 01/2003)|
|4.||Di Cesare, Paul E: 7 articles (07/2014 - 03/2004)|
|5.||Holmdahl, Rikard: 6 articles (09/2013 - 01/2002)|
|6.||Hecht, Jacqueline T: 6 articles (01/2010 - 03/2002)|
|7.||Briggs, Michael D: 5 articles (01/2015 - 06/2005)|
|8.||Kraus, V B: 5 articles (11/2012 - 10/2001)|
|9.||Jordan, Joanne M: 5 articles (08/2011 - 03/2003)|
|10.||Heinegård, D: 5 articles (11/2006 - 01/2000)|
09/01/2011 - "A mutation in cartilage oligomeric matrix protein (COMP) causes early-onset osteoarthritis in a large kindred study."
05/01/2011 - "To study the levels of cartilage oligomeric matrix protein (COMP) and matrix metalloproteinase-3 (MMP-3) in the serum fluid of osteoarthritic rabbit models and their relationships with the severity of pathological changes, so as to investigate their correlation with osteoarthritis (OA). "
03/01/2003 - "In the present study, we examined associations between serum levels of cartilage oligomeric matrix protein (COMP) and ethnicity (African American or Caucasian) and sex in the Johnston County Osteoarthritis Project, a population-based study of OA in rural North Carolina. "
01/01/2001 - "Identification of sequence polymorphisms of the COMP (cartilage oligomeric matrix protein) gene and association study in osteoarthrosis of the knee and hip joints."
01/01/2015 - "Cartilage oligomeric matrix protein and matrix metalloproteinase-3 expression in the serum and joint fluid of a reversible osteoarthritis rabbit model."
06/01/2008 - "Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT study."
01/01/2004 - "This study examined the serum and synovial fluid concentrations of cartilage oligomeric matrix protein (COMP) in relation to the evolution of joint cartilage damage and the requirement for surgery in 125 patients with rheumatoid arthritis (RA). "
01/01/2015 - "Serum cartilage oligomeric matrix protein (COMP) level is a new marker of joint destruction in patients with rheumatoid arthritis (RA), and a new means of identifying patients with progressive joint damage. "
01/01/2014 - "to analyze the correlation between Receptor activator of nuclear factor-κβ ligand (RANKL), Osteoprotegrin (OPG) serum level with cartilage oligomeric matrix protein (COMP) serum level as a marker of cartilage degradation in rheumatoid arthritis patients. "
08/01/2009 - "Cartilage oligomeric matrix protein (COMP) has been identified as a prognostic marker of progressive joint destruction in rheumatoid arthritis. "
|3.||Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
08/01/2009 - "Cartilage oligomeric matrix protein in patients with juvenile idiopathic arthritis: relation to growth and disease activity."
05/01/2006 - "Clinical significance of decreased serum concentration of cartilage oligomeric matrix protein in systemic juvenile idiopathic arthritis."
01/01/2009 - "In this study, we determined serum cartilage oligomeric matrix protein (COMP) levels in systemic juvenile idiopathic arthritis (sJIA) patients during both the active and the remission phases to investigate how the growth cartilage turnover changed under tocilizumab treatment. "
01/01/2009 - "Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab."
06/01/2007 - "Cartilage oligomeric matrix protein (COMP) is a tissue-specific noncollagenous protein that was first detected in the serum and the synovial fluid of patients suffering from rheumatic disorders, such as rheumatoid arthritis, reactive arthritis, juvenile chronic arthritis, and osteoarthritis. "
|4.||Rheumatic Diseases (Rheumatism)
06/01/2007 - "Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments."
01/01/2004 - "Serum levels of cartilage oligomeric matrix protein are elevated in rheumatoid arthritis, but not in inflammatory rheumatic diseases such as psoriatic arthritis, reactive arthritis, Raynaud's syndrome, scleroderma, systemic lupus erythematosus, vasculitis and Sjögren's syndrome."
08/01/2012 - "The study aimed determining whether assessment of cartilage oligomeric matrix protein (COMP) degradation products could serve as a serological disease course and therapeutic response predictor in arthritis. "
07/01/2008 - "To develop a new mouse model for arthritis using cartilage oligomeric matrix protein (COMP) and to study the role of major histocompatibility complex (MHC) and Ncf1 genes in COMP-induced arthritis (COMPIA). "
01/01/2008 - "In this article we summarise briefly their multiple uses and reflect on how the study reported in a previous edition of Arthritis Research & Therapy should promote further investigation of cartilage oligomeric matrix protein (COMP). "
01/01/2010 - "This review briefly summarizes the structural organization and functional roles of ADAMTSs in normal and pathological conditions, focusing on members that are known to be involved in the degradation of extracellular matrix and loss of cartilage in arthritis, including the aggrecanases (ADAMTS-4 and ADAMTS-5), ADAMTS-7 and ADAMTS-12, the latter two are associated with cartilage oligomeric matrix protein (COMP), a component of the cartilage extracellular matrix (ECM). "
01/01/2009 - "Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis."
|1.||Collagen Type II (Type II Collagen)
|3.||TNFR-Fc fusion protein (etanercept)
|4.||Immunoglobulin M (IgM)
|5.||Biological Markers (Surrogate Marker)
|6.||Hyaluronic Acid (Hyaluronan)
|7.||Proteins (Proteins, Gene)
|8.||cyclic citrullinated peptide
|2.||Homologous Transplantation (Allograft)